Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma
NCT04996758Phase 2Completed
- Sponsor
- Sun Yat-sen University
- Start
- Oct 2021
- Primary completion
- Sep 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab, anlotinib in nasopharyngeal carcinoma (NPC), sponsored by Sun Yat-sen University. Started Oct 2021; status: completed.
02
Drugs
toripalimabanlotinib
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT04996758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04996758.